8:30 am Check-In & Coffee
9:15 am Chair’s Opening Remarks
Understanding The Effect of Linker Differentiation on Toxicity to to Reduce Off-Target Toxicities
9:30 am Analyzing the Difference in Toxicity Profiles when Linker Stability is Altered in Order to Understand the Root Cause of Toxicity
Synopsis
- Comparing the benefits of more stable linkers compared to more cleavable linkers
- Comprehending the mechanism of linker technology to understand premature/late release of the payload
- Investigating the relationship between linker type and the resulting toxicity
10:00 am Sharing Data on Pre-Clinical Toxicity Results Upon Use of Cleavable vs Non-Cleavable Linkers
Synopsis
Understanding the relationship of linker stability to tissue-specific toxicities
Optimizing linker stability to improve the toxicity profile of ADCs.
Leveraging knowledge of linkers for the development of novel ADCs
10:30 am Evaluating the Differences in Toxicity of Novel Multilink Linker-Payload Technology
Synopsis
- Comparing two ADCs with the same antibody and payload to demonstrate the importance of new linker technologies
- Evaluating the toxicity profile of different linker-payload to improve the therapeutic index
- Comparing two schedules of treatment in the hope of optimizing the efficacy and the toxicity profile
11:00 am Morning Break & Networking
Synopsis
This session is an opportunity to connect with peers working within the ADC Toxicity world, to have important conversations to overcome shared challenges, and plot paths to see future successes within the field
Improving Prediction of Toxicities through a Reverse Translational Approach
11:30 am Translating from the Clinic to in vitro and Back to Gain an Understanding of Mechanisms of Toxicity
12:00 pm Panel – Bench to Bedside & Back – Assessing the Benefits of a Reverse Translational Approach When Minimizing ADC Toxicities
Synopsis
- Viewing the ways toxicities present themselves clinically to consider what can be done preclinically to mitigate these effects
- Transferring from human studies to animal studies to obtain a deeper understanding of how different ADCs are distributed across healthy tissues
- Understanding potential biomarkers for predicting toxicities which present in humans and being able to connect this back to the pre-clinical stage
- Navigating the concept of translating back and mechanistically blocking the toxicity in vitro
12:45 pm Lunch & Networking
Retooling your ADC to Increase Therapeutic Index
1:45 pm Employing Payloads with Dual MoA to Improve Therapeutic Window of ADC
Synopsis
- Introducing novel camptothecins with moderate Top1 inhibition, strong anti-tumor potency and improved safety profile
- Comprehending how dual MoA of novel payloads can contribute to improved therapeutic windows
- Investigating applications of dual MoA to improve general safety profiles of ADCs
2:15 pm Harnessing and Evaluating the Use of Bicycle Toxin Conjugates in Place of Traditional ADCs to Reduce Toxicities
Synopsis
- Exploring the use of bicycle peptides as an alternative to antibodies for the delivery of cytotoxic payloads to reduce toxicities
- Comparison of the toxicity profile of BTCs with standard ADCs
- Exploring physiochemical properties to reduce off target toxicity
2:45 pm Improving your Therapeutic Index Using Novel Nuclear Delivered ADCs
Synopsis
- Discover how by understanding target biology, and careful tailoring of ADC design is the key to achieving high therapeutic index
- Learn the possibilities surrounding the use of AGX101 to increase the therapeutic index up to 10-fold
- Evaluate the use of nuclear-delivered antibody-drug conjugates, which are now in the clinic, to reduce toxicity
3:15 pm Chair’s Closing Remarks
3:20 pm End of 2nd ADC Toxicity Summit
